$AIP

RAZA SAIYED ATIQ sold $31K of AIP (indirect holdings)

RAZA SAIYED ATIQ sold 800 indirectly-held shares of Arteris, Inc. (AIP) at $38.46 on 2026-06-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · RAZA SAIYED ATIQ
Published Jun 4, 2026, 10:58 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 4, 2026, 11:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AIP
Neutral
medium confidence
Mentioned
$AIP
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AIPNeutralLow
01

Why it matters

The disclosure updates the insider activity record but does not, by itself, provide new operational or financial information. The 10b5-1 designation typically lowers interpretive weight.

02

Market read

AIP receives an insider-selling update; expected impact is modest unless paired with other catalysts.

03

What to watch

Traders may overreact to the headline; the key differentiator is the 10b5-1 pre-arrangement and the small absolute dollar amount (~$31k).

Relevance 6/10Novelty 3/10Timing: SEC Form 4 filed today; sale occurred 2026-06-03.

Background

This is an SEC Form 4 insider transaction for Arteris, Inc. (AIP) showing a director’s open-market sale.

Company-level read

Ticker impact

$AIPNeutralMedium confidence
Context

Arteris director RAZA SAIYED ATIQ sold 800 shares in an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Limited near-term impact; any reaction likely muted unless accompanied by other negative company news.

Evidence & confidence

The filing is an ownership-change disclosure with a stated 10b5-1 plan, reducing the probability of new fundamental information.

Market effects

No clear sector read-through from a single director 10b5-1 sale.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, the disclosure may be largely mechanical rather than a bearish signal.

Key entities

  • Arteris, Inc.

    US-listed company whose director filed the Form 4 insider sale.

  • RAZA SAIYED ATIQ

    Director who sold 800 shares of AIP under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AIPMedAI 8/10

Arteris (AIP) Q2 2026 Earnings Call Transcript

Arteris, Inc. (AIP) reported Q2 2026 revenue of $24.1 million, up 46% year over year. ACV plus royalties were $99.5 million, up 44%, and remaining performance obligation was $135 million, up 36%. Cash and investments rose to $123 million after an at-the-market raise. Full-year 2026 revenue guidance was raised to $95-$98 million.

MedAI 8/10

Arteris Inc. raises FY26 sales guidance to $95-98M range

Arteris Inc. raised its FY2026 revenue guidance to $95.0 million to $98.0 million, up from $91.0 million to $95.0 million previously. The new range is above the $94.578 million analyst consensus estimate, reflecting stronger-than-expected demand for its NoC interconnects and design automation tools, according to the company.

$AIPHighAI 9/10

Arteris, Inc. (AIP): Results of Operations and Financial Condition

Arteris, Inc. (AIP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Arteris Announces Financial Results for the Second Quarter and Estimated Third Quarter and Updated Full Year 2026 Guidance CAMPBELL, Calif. - August 6, 2026 - Arteris, Inc. (Nasdaq: AIP), a leading provider of semiconductor technology for accelerating innovation in the AI era, to